Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

as well as their corporate headquarters. Germany-based Boehringer Ingelheim scored highly for wellbeing – particularly for its commitment to prioritising mental health for employees – and ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

BERLIN, Oct. 15, 2024 /PRNewswire/ -- Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...

Learn more at https://www.boehringer-ingelheim.com. This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

Learn more at https://www.boehringer-ingelheim.com. This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...